With Acomplia the fact that it can help you lose weight is not disputed

Sanofi Aventis are trying very hard to show that their weight loss drug Acomplia is completely different to the other weight loss drugs Xenical and especially Reductil. This is because in testing they can show that Acomplia not only helps people to stop thinking about food as an appetite suppressant but it also has good effects on cholesterol levels and blood sugar levels too. When they applied to the relevant health authorities in Europe to get the approvals for the drug they did not just mention weight loss for the approval but also that it was beneficial for metabolic function. If Acomplia can become known not only as a weight loss drug but also as a drug that diabetics and people who are suffering from obesity related conditions could benefit from the financial rewards for Sanofi will be huge.

Is Acomplia really going to be different, that is the big question that all health authorities are asking and some of them are a tad sceptical believing that the only reason that Sanofi are pushing the other benefits of its weight loss drug are so that Acomplia will become reimbursable by insurance companied that normally do not pay up for weight loss drugs.

When a new drug is launched there has always been a huge amount spent on extensive testing to confirm that it is safe and effective. In 99.9% of cases no new effects are noted and the drugs go on sale for years and years with no problems. The weight loss drugs Reductil and Xenical were extensively tested before they were launched and no problems have been reported except when they have been incorrectly used or used by the wrong people.

With Acomplia the fact that it can help you lose weight is not disputed but whether it can have a very relevant effect on other obesity related illnesses will be become more apparent over time. Some people think that it is the simple weight loss that the Acomplia causes that is what causes the lowering of blood sugar levels and other benefits but Sanofi claims that the drug lowers the levels over and above what would usually be expected.